The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Advances in the Development of Anti-Toxoplasma gondii Vaccines: Challenges, Opportunities, and Perspectives
Open accessAbstract
Important progress has been made in understanding how immunity is elicited against Toxoplasma gondii - a complex pathogen with multiple mechanisms of immune evasion. Many vaccine candidates have been tested using various strategies in animal models. However, none of these strategies has delivered as yet, and important challenges remain in the development of vaccines that can eliminate the tissue cysts and/or fully block vertical transmission. In this review, we provide an overview of the current understanding of the host immune response to T. gondii infection and summarize the key limitations for the development of an effective, safe, and durable toxoplasmosis vaccine. We also discuss how the successes and failures in developing and testing vaccine candidates have provided a roadmap for future vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
Roozbehani, M., Falak, R., Mohammadi, M., Hemphill, A., Razmjou, E., Meamar, A. R., Masoori, L., Khoshmirsafa, M., Moradi, M., & Gharavi, M. J. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.068 · Cited by 54
Research works printed but not linked: 82
- Montoya, 2004, Toxoplasmosis, Lancet, 363, 1965, 10.1016/S0140-6736(04)16412-X · DOI · Paper page
- Robert-Gangneux, 2012, Epidemiology of and diagnostic strategies for toxoplasmosis, Clin. Microbiol. Rev., 25, 264, 10.1128/CMR.05013-11 · DOI · Paper page
- Elsheikha, 2008, Congenital toxoplasmosis: priorities for further health promotion action, Public Health, 122, 335, 10.1016/j.puhe.2007.08.009 · DOI · Paper page
- Wang, 2017, Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis, Lancet HIV, 4, e177, 10.1016/S2352-3018(17)30005-X · DOI · Paper page
- Dunay, 2018, Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice, Clin. Microbiol. Rev., 31, 10.1128/CMR.00057-17 · DOI · Paper page
- Buxton, 1995, A commercial vaccine for ovine toxoplasmosis, Parasitology, 110, S11, 10.1017/S003118200000144X · DOI · Paper page
- Yarovinsky, 2014, Innate immunity to Toxoplasma gondii infection, Nat. Rev. Immunol., 14, 109, 10.1038/nri3598 · DOI · Paper page
- Pittman, 2015, Long-term relationships: the complicated interplay between the host and the developmental stages of Toxoplasma gondii during acute and chronic infections, Microbiol. Mol. Biol. Rev., 79, 387, 10.1128/MMBR.00027-15 · DOI
- Hunter, 2012, Modulation of innate immunity by Toxoplasma gondii virulence effectors, Nat. Rev. Microbiol., 10, 766, 10.1038/nrmicro2858 · DOI · Paper page
- Sayles, 2000, B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii, Infect. Immun., 68, 1026, 10.1128/IAI.68.3.1026-1033.2000 · DOI · Paper page
- Gigley, 2009, Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain, Infect. Immun., 77, 5380, 10.1128/IAI.00649-09 · DOI
- Hwang, 2015, CD8+ T cell immunity in an encephalitis model of Toxoplasma gondii infection, Semin. Immunopathol., 37, 271, 10.1007/s00281-015-0483-7 · DOI
- Dard, 2016, Relevance of and new developments in serology for toxoplasmosis, Trends Parasitol., 32, 492, 10.1016/j.pt.2016.04.001 · doi:10.1016/j.pt.2016.04.001
- Li, 2018, Moving towards improved vaccines for Toxoplasma gondii, Expert Opin. Biol. Ther., 18, 273, 10.1080/14712598.2018.1413086 · DOI
- Zhang, 2015, Recent advances in developing vaccines against Toxoplasma gondii: an update, Expert Rev. Vaccines, 14, 1609, 10.1586/14760584.2015.1098539 · DOI
- Hiszczyńska-Sawicka, 2014, Veterinary vaccines against toxoplasmosis, Parasitology, 141, 1365, 10.1017/S0031182014000481 · DOI
- Li, 2014, Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic Toxoplasma gondii infection in mice, Vaccine, 32, 3058, 10.1016/j.vaccine.2014.03.042 · DOI
- Wang, 2018, Protective immune response against Toxoplasma gondii elicited by a novel yeast-based vaccine with microneme protein 16, Vaccine, 36, 3943, 10.1016/j.vaccine.2018.05.072 · DOI
- Lee, 2018, Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection, Vaccine, 36, 5692, 10.1016/j.vaccine.2018.08.016 · DOI
- Machado, 2010, Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity, Vaccine, 28, 3247, 10.1016/j.vaccine.2010.02.003 · DOI
- Buxton, 1991, Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant, Vet. Rec., 129, 89, 10.1136/vr.129.5.89 · DOI · Paper page
- Wang, 2016, The past, present, and future of genetic manipulation in Toxoplasma gondii, Trends Parasitol., 32, 542, 10.1016/j.pt.2016.04.013 · DOI
- Sloves, 2015, Apical organelle secretion by Toxoplasma controls innate and adaptive immunity and mediates long-term protection, J. Infect. Dis., 212, 1449, 10.1093/infdis/jiv250 · doi:10.1093/infdis/jiv250
- Kim, 2005, Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence, J. Immunol., 174, 8038, 10.4049/jimmunol.174.12.8038 · DOI
- Fang, 2016, Nanoparticle-based modulation of the immune system, Annu. Rev. Chem. Biomol. Eng., 7, 305, 10.1146/annurev-chembioeng-080615-034446 · DOI
- Mintern, 2013, Targeting dendritic cells: the role of specific receptors in the internalization of polymer capsules, Adv. Healthc. Mater., 2, 940, 10.1002/adhm.201200441 · doi:10.1002/adhm.201200441
- Skwarczynski, 2010, Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system, Angew. Chem. Int. Ed. Engl., 49, 5742, 10.1002/anie.201002221 · DOI · Paper page
- Dacoba, 2017, Modulating the immune system through nanotechnology, Semin. Immunol., 34, 78, 10.1016/j.smim.2017.09.007 · DOI
- Assolini, 2017, Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications, Parasitol. Res., 116, 1603, 10.1007/s00436-017-5458-2 · DOI
- Rahimi, 2017, Immunological evaluation of a DNA cocktail vaccine with co-delivery of calcium phosphate nanoparticles (CaPNs) against the Toxoplasma gondii RH strain in BALB/c mice, Parasitol. Res., 116, 609, 10.1007/s00436-016-5325-6 · DOI
- Théry, 2002, Exosomes: composition, biogenesis and function, Nat. Rev. Immunol., 2, 569, 10.1038/nri855 · DOI · Paper page
- Coakley, 2015, Exosomes and other extracellular vesicles: the new communicators in parasite infections, Trends Parasitol., 31, 477, 10.1016/j.pt.2015.06.009 · DOI · Paper page
- Beauvillain, 2009, Exosomes are an effective vaccine against congenital toxoplasmosis in mice, Vaccine, 27, 1750, 10.1016/j.vaccine.2009.01.022 · DOI
- Li, 2018, Characterization of exosomes derived from Toxoplasma gondii and their functions in modulating immune responses, Int. J. Nanomed., 13, 467, 10.2147/IJN.S151110 · DOI
- Astronomo, 2010, Carbohydrate vaccines: developing sweet solutions to sticky situations?, Nat. Rev. Drug. Discov., 9, 308, 10.1038/nrd3012 · DOI · Paper page
- Rodrigues, 2015, Parasite glycobiology: a bittersweet symphony, PLoS Pathog., 11, 10.1371/journal.ppat.1005169 · DOI
- Jaurigue, 2017, Parasite carbohydrate vaccines, Front. Cell. Infect. Microbiol., 7, 248, 10.3389/fcimb.2017.00248 · DOI
- Debierre-Grockiego, 2007, Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii, J. Immunol., 179, 1129, 10.4049/jimmunol.179.2.1129 · DOI · Paper page
- Götze, 2015, Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a Toxoplasma gondii mouse challenge model, Glycobiology, 25, 984, 10.1093/glycob/cwv040 · DOI
- Howe, 1995, Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease, J. Infect. Dis., 172, 1561, 10.1093/infdis/172.6.1561 · DOI · Paper page
- Khan, 2007, Recent transcontinental sweep of Toxoplasma gondii driven by a single monomorphic chromosome, Proc. Natl. Acad. Sci. U. S. A., 104, 14872, 10.1073/pnas.0702356104 · DOI · Paper page
- Saeij, 2005, Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host, Trends Parasitol., 21, 476, 10.1016/j.pt.2005.08.001 · DOI · Paper page
- Su, 2012, Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages, Proc. Natl. Acad. Sci. U. S. A., 109, 5844, 10.1073/pnas.1203190109 · DOI · Paper page
- Shwab, 2018, Human impact on the diversity and virulence of the ubiquitous zoonotic parasite Toxoplasma gondii, Proc. Natl. Acad. Sci. U. S. A., 115, E6956, 10.1073/pnas.1722202115 · DOI
- Lorenzi, 2016, Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic Toxoplasma gondii genomes, Nat. Commun., 7, 10.1038/ncomms10147 · DOI · Paper page
- Jensen, 2015, Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination, mBio, 6, 10.1128/mBio.02280-14 · DOI
- Dao, 2001, Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype, Int. J. Parasitol., 31, 63, 10.1016/S0020-7519(00)00151-X · DOI
- Wang, 2017, Proteomic differences between developmental stages of Toxoplasma gondii revealed by iTRAQ-based quantitative proteomics, Front. Microbiol., 8, 985, 10.3389/fmicb.2017.00985 · DOI
- Szabo, 2017, Toxoplasma gondii: one organism, multiple models, Trends Parasitol., 33, 113, 10.1016/j.pt.2016.11.007 · DOI
- Koblansky, 2013, Recognition of profilin by Toll-like receptor 12 is critical for host resistance to Toxoplasma gondii, Immunity, 38, 119, 10.1016/j.immuni.2012.09.016 · DOI · Paper page
- Howard, 2011, The IRG protein-based resistance mechanism in mice and its relation to virulence in Toxoplasma gondii, Curr. Opin. Microbiol., 14, 414, 10.1016/j.mib.2011.07.002 · DOI
- Hakimi, 2017, Toxoplasma effectors targeting host signaling and transcription, Clin. Microbiol. Rev., 30, 615, 10.1128/CMR.00005-17 · DOI · Paper page
- Bougdour, 2013, Host cell subversion by Toxoplasma GRA16, an exported dense granule protein that targets the host cell nucleus and alters gene expression, Cell Host Microbe, 13, 489, 10.1016/j.chom.2013.03.002 · DOI · Paper page
- Braun, 2013, A Toxoplasma dense granule protein, GRA24, modulates the early immune response to infection by promoting a direct and sustained host p38 MAPK activation, J. Exp. Med., 210, 2071, 10.1084/jem.20130103 · DOI · Paper page
- Olias, 2016, Toxoplasma effector recruits the Mi-2/NuRD complex to repress STAT1 transcription and block IFN-γ-dependent gene expression, Cell Host Microbe, 20, 72, 10.1016/j.chom.2016.06.006 · DOI · Paper page
- Gay, 2016, Toxoplasma gondii TgIST co-opts host chromatin repressors dampening STAT1-dependent gene regulation and IFN-γ-mediated host defenses, J. Exp. Med., 213, 1779, 10.1084/jem.20160340 · DOI · Paper page
- Ma, 2014, Selective and strain-specific NFAT4 activation by the Toxoplasma gondii polymorphic dense granule protein GRA6, J. Exp. Med., 211, 2013, 10.1084/jem.20131272 · DOI
- Rosowski, 2011, Strain-specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii dense granule protein, J. Exp. Med., 208, 195, 10.1084/jem.20100717 · DOI · Paper page
- Butcher, 2011, Toxoplasma gondii rhoptry kinase ROP16 activates STAT3 and STAT6 resulting in cytokine inhibition and arginase-1-dependent growth control, PLoS Pathog., 7, 10.1371/journal.ppat.1002236 · DOI · Paper page
- Jensen, 2011, Toxoplasma polymorphic effectors determine macrophage polarization and intestinal inflammation, Cell Host Microbe, 9, 472, 10.1016/j.chom.2011.04.015 · DOI · Paper page
- Etheridge, 2014, The Toxoplasma pseudokinase ROP5 forms complexes with ROP18 and ROP17 kinases that synergize to control acute virulence in mice, Cell Host Microbe, 15, 537, 10.1016/j.chom.2014.04.002 · DOI · Paper page
- Jeffers, 2018, A latent ability to persist: differentiation in Toxoplasma gondii, Cell. Mol. Life Sci., 75, 2355, 10.1007/s00018-018-2808-x · doi:10.1007/s00018-018-2808-x
- Holmes, 2017, Translational control in the latency of apicomplexan parasites, Trends Parasitol., 33, 947, 10.1016/j.pt.2017.08.006 · DOI
- Lesage, 2018, Cooperative binding of ApiAP2 transcription factors is crucial for the expression of virulence genes in Toxoplasma gondii, Nucleic Acids Res., 46, 6057, 10.1093/nar/gky373 · DOI
- Radke, 2018, Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis, PLoS Pathog., 14, 10.1371/journal.ppat.1007035 · DOI
- Dubey, 1999, Infection and immunity with the RH strain of Toxoplasma gondii in rats and mice, J. Parasitol., 85, 657, 10.2307/3285739 · doi:10.2307/3285739
- Damania, 2014, What lies within: coinfections and immunity, Cell Host Microbe, 16, 145, 10.1016/j.chom.2014.07.014 · DOI
- Inclan-Rico, 2018, First responders: innate immunity to helminths, Trends Parasitol., 34, 861, 10.1016/j.pt.2018.08.007 · DOI
- Sette, 2010, Reverse vaccinology: developing vaccines in the era of genomics, Immunity, 33, 530, 10.1016/j.immuni.2010.09.017 · DOI · Paper page
- Rinaudo, 2009, Vaccinology in the genome era, J. Clin. Invest., 119, 2515, 10.1172/JCI38330 · DOI · Paper page
- Kassegne, 2016, Immunomic approaches for antigen discovery of human parasites, Expert Rev. Proteomics, 13, 1091, 10.1080/14789450.2016.1252675 · DOI
- Goodswen, 2018, A gene-based positive selection detection approach to identify vaccine candidates using Toxoplasma gondii as a test case protozoan pathogen, Front. Genet., 9, 332, 10.3389/fgene.2018.00332 · DOI
- Gourlay, 2017, Structure and computation in immunoreagent design: from diagnostics to vaccines, Trends Biotechnol., 35, 1208, 10.1016/j.tibtech.2017.06.018 · DOI
- Fox, 2002, De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii, Nature, 415, 926, 10.1038/415926a · DOI · Paper page
- Ismael, 2006, Mic1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice, J. Infect. Dis., 194, 1176, 10.1086/507706 · DOI
- Fox, 2010, Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii, Infect. Immun., 78, 3744, 10.1128/IAI.00287-10 · DOI
- Fox, 2015, Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection, Infect. Immun., 83, 2148, 10.1128/IAI.02756-14 · DOI
- Lagal, 2015, AMA1-deficien Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity, Infect. Immun., 83, 2475, 10.1128/IAI.02606-14 · DOI
- Arroyo-Olarte, 2015, Phosphatidylthreonine and lipid-mediated control of parasite virulence, PLoS Biol., 13, 10.1371/journal.pbio.1002288 · DOI
- Wang, 2017, Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice, Front. Immunol., 8, 730, 10.3389/fimmu.2017.00730 · DOI · Paper page
- Wang, 2018, Live attenuated Pru:Δcdpk2 strain of Toxoplasma gondii protects against acute, chronic, and congenital toxoplasmosis, J. Infect. Dis., 218, 768, 10.1093/infdis/jiy211 · DOI
- Mévélec, 2010, Mic1-3 knockout Toxoplasma gondii is a good candidate for a vaccine against T. gondii-induced abortion in sheep, Vet. Res., 41, 49, 10.1051/vetres/2010021 · DOI
Cited by
Control of human toxoplasmosis
Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G. (2021) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.11.001 · Cited by 286
Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis
Elsheikha, H. M., Marra, C. M., & Zhu, X.-Q. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-19 · Cited by 262
Self-citationAdvances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development
Chu, K.-B., & Quan, F.-S. (2021) · Vaccines · doi:10.3390/vaccines9050413 · Cited by 92
Wang, J.-L., Liang, Q.-L., Li, T.-T., He, J.-J., Bai, M.-J., Cao, X.-Z., Elsheikha, H. M., & Zhu, X.-Q. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900410 · Cited by 35
Self-citationLi, D., Zhang, Y., Li, S., & Zheng, B. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1145114 · Cited by 22
Metadata
- Authors
- Wang, J.-L., Zhang, N.-Z., Li, T.-T., He, J.-J., Elsheikha, H. M., & Zhu, X.-Q.
- Venue
- Trends in Parasitology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 35
- Issue
- 3
- Pages
- 239-253
- ISSN
- 1471-4922 (ISSN-L)
- OpenAlex
- W2912655637
- Cited by
- 187
- References
- 3
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- National Natural Science Foundation of China (31802180, 31230073)
- National Key Research and Development Program of China (2017YFD0501304)
- International Science and Technology Cooperation Project of Gansu Provincial Key Research and Development Program (17JR7WA031)
- Elite Program of Chinese Academy of Agricultural Sciences, and the Agricultural Science and Technology Innovation Program (CAAS-ASTIP-2016-LVRI-03)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.